Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative precision medicines for serious conditions of unmet medical need in oncology. The company is focused on advancing two main drug candidates, NXP800 and NXP900, with ongoing clinical trials and strategic collaborations aimed at improving cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Nuvectis Pharma, Inc.
Products
Oral small‑molecule GCN2 kinase activator (clinical candidate)
An orally bioavailable small molecule that activates the GCN2 kinase to induce an integrated stress response and reduce bulk protein synthesis, evaluated in preclinical models and early clinical trials for selected oncology indications.
Oral small‑molecule SRC family kinase inhibitor (clinical candidate)
An orally bioavailable small molecule designed to inhibit the SRC family kinases, including catalytic and scaffolding functions, developed for oncology indications and evaluated in early clinical dose‑escalation studies.
Oral small‑molecule GCN2 kinase activator (clinical candidate)
An orally bioavailable small molecule that activates the GCN2 kinase to induce an integrated stress response and reduce bulk protein synthesis, evaluated in preclinical models and early clinical trials for selected oncology indications.
Oral small‑molecule SRC family kinase inhibitor (clinical candidate)
An orally bioavailable small molecule designed to inhibit the SRC family kinases, including catalytic and scaffolding functions, developed for oncology indications and evaluated in early clinical dose‑escalation studies.
Services
Clinical trial collaboration and investigator‑sponsored trial partnerships
Collaborative execution of investigator‑initiated and company‑sponsored early‑phase oncology trials with academic partners and clinical sites.
Preclinical pharmacology and translational research
Design and execution of preclinical efficacy, mechanism‑of‑action and biomarker studies to support candidate selection and clinical translation.
Clinical trial collaboration and investigator‑sponsored trial partnerships
Collaborative execution of investigator‑initiated and company‑sponsored early‑phase oncology trials with academic partners and clinical sites.
Preclinical pharmacology and translational research
Design and execution of preclinical efficacy, mechanism‑of‑action and biomarker studies to support candidate selection and clinical translation.
Expertise Areas
- Early‑phase clinical development
- Precision oncology drug discovery
- Kinase‑targeted small‑molecule therapeutics
- Preclinical pharmacology and in vivo modeling
Key Technologies
- Small‑molecule kinase modulation
- Multi‑omics biomarker analysis
- Xenograft and PDX tumor models
- Cell‑based proliferation and signaling assays